Becerril-Bautista B, Jímenez-Uscanga RD, Vargas-Camaño ME, Alonso-Bello CD, Lozano-Patiño F, et al. (2018) Glycophosphopeptical and Specific Immunotherapy Effect in Allergic Rhinitis. Int J Aller Medications 4:036.


© 2018 Becerril-Bautista B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ORIGINAL ARTICLE | OPEN ACCESS DOI: 10.23937/2572-3308.1510036

Glycophosphopeptical and Specific Immunotherapy Effect in Allergic Rhinitis

Becerril-Bautista Baltazar, Jímenez-Uscanga Rubén Darío, Vargas-Camaño María Eugenia, Alonso-Bello César Daniel*, Lozano-Patiño Fernando, Sánchez-León María del Carmen, Juárez-Santiago Lucero and María Isabel Castrejón-Vázquez*

Clinical Immunology and Allergy Department, ISSSTE Centro Médico Nacional 20 de Noviembre, Mexico City, Mexico



Allergic rhinitis (AR) is an inflammatory disease mediated by immunoglobulin E (IgE) following exposure of the nasal mucosa to an allergen. Glycophosphopeptical (GFP) is a molecule composed of polysaccharides of fungal origin and proteins of vegetal origin, adsorbed in an inorganic phosphate-sulfate-calcium matrix, stimulates the innate immunity, during infectious processes.


The objective of the study was to analyze the clinical response of specific immunotherapy (SIT) and the use of GFP in patients with allergic rhinitis.


An observational, retrospective, comparative and analytical study was carried out, with non-probabilistic sampling of consecutive cases. We reviewed records of patients diagnosed with allergic rhinitis treated at least 6 months with GFP and SIT. Descriptive statistics, Student's t and Wilcoxon's test were used for comparation.


The total group was 22 (36.6%) men and 38 (63.3%) women, with a mean age of 31 years (4-58), the group with SIT 9 (30%) men and 21 (70%) women; The SIT + GFP group with 13 (43.3%) men and 17 (56.6%) women. The two groups presented clinical improvement, related to the number of infections and improvement of symptoms. When comparing both groups (SIT vs. SIT + GFP) after treatment, there were no statistically significant differences related to the number of infections (P < 0.061) and no significant differences between the change in the ARIA score in the group with SIT (P = 0.536) and SIT + GFP (P = 0.619).


GFP added to SIT does not produce superior clinical improvement in patients with allergic rhinitis compared to SIT alone.